OTC · Biotechnology

Avacta Group Plc (AVCTF) Stock

$0.94 +3.71% OTC: AVCTF Healthcare

Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms.

Valuation

MetricValue
Price$0.94
Market Cap$440.30M
P/E Ratio-7.36
P/B Ratio120.81
P/S Ratio2839.44
EPS (TTM)$-0.10
52-Week High$1.23
52-Week Low$0.64
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1900.00%
ROA-130.46%
ROCE-927.45%
Gross Margin100.00%
Operating Margin-28680.70%
Net Margin0.00%
Debt/Equity6.02
Current Ratio0.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$10.0M$23.0M$0$0
Operating Profit$-29.0M$-33.0M$-27.0M$-33.0M$-30.0M
Net Profit$-26.0M$-39.0M$-25.0M$-53.0M$-38.0M
EPS$-0.11$-0.15$-0.09$-0.16$-0.10
Op Margin-988.9%-338.2%-114.9%-28812.4%-26756.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$47.0M$93.0M$73.0M$48.0M$29.0M
Total Liabilities$6.0M$74.0M$51.0M$39.0M$27.0M
Cash$26.0M$42.0M$17.0M$13.0M$17.0M
Borrowings$2.0M$24.0M$23.0M$23.0M$15.0M

Latest News

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors GlobeNewswire · Jul 8, 2026 Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 GlobeNewswire · Jun 1, 2026 Unaudited Preliminary Results for the Year Ended December 31, 2025 GlobeNewswire · May 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-21.0M$-16.0M$-15.0M$-24.0M$-25.0M
Investing Cash Flow$37.0M$-26.0M$-10.0M$-2.0M$10.0M
Financing Cash Flow$0$47.0M$0$-3.0M$-4.0M
Net Cash Flow$-2.0M$16.0M$-25.0M$1.0M$5.0M
Free Cash Flow$-22.0M$-17.0M$-16.0M$-24.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.07
EV / EBITDA-11.14
FCF Yield-7.73%
Quick Ratio0.89
Interest Coverage-4.29
Return 1Y34.88%
Return 3Y-39.57%
Return 5Y—

Ownership

Insiders Held1.18%
Institutions Held8.38%
Institutions Float Held8.48%
Institutional HolderSharesReport Date
Thrivent International Allocation Fund47,2922023-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Avacta Group Plc

Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.

Avacta Group Plc is headquartered in GB.

Avacta Group Plc (AVCTF) stock trades at $0.94 with a market capitalization of $440.30M. The stock is valued at a price-to-earnings (P/E) ratio of -7.36, price-to-book of 120.81, price-to-sales of 2839.44. Over the past 52 weeks the stock has ranged between $0.64 and $1.23, and currently trades 23.6% below its 52-week high.

On profitability, Avacta Group Plc generates a return on equity (ROE) of -1900.00%, return on capital employed of -927.45%, an operating margin of -28680.70%, a net profit margin of 0.00%.

Official website: www.avacta.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides